• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ:ALVO)

3.740 +0.600 (+19.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,483,038
Open 3.160
Bid (Size) 3.710 (100)
Ask (Size) 3.790 (1,000)
Prev. Close 3.140
Today's Range 3.150 - 3.780
52wk Range 2.940 - 11.85
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Alvotech Nears Inflection Point With 5 U.S. Biosimilars Targeted by Year-End ↗
Today 0:02 EDT
Alvotech (NASDAQ:ALVO) is at an “inflection point” after more than a decade of investment in its biosimilar platform, Founder and Executive Chairman Róbert Wessman said at the Jefferies Global... 
Via MarketBeat
News headline image
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
June 04, 2026
From Alvotech
Via GlobeNewswire

Performance

YTD
-25.2%
-25.2%
1 Month
+6.9%
+6.9%
3 Month
-10.1%
-10.1%
6 Month
-26.2%
-26.2%
1 Year
-65.5%
-65.5%

More News

Read More
News headline image
Main Results of 2026 Annual and Extraordinary General Meeting
June 03, 2026
From Alvotech
Via GlobeNewswire
News headline image
Alvotech to present at upcoming investor conferences in June
June 02, 2026
From Alvotech
Via GlobeNewswire
Alvotech (NASDAQ:ALVO) Q1 2026 Results Miss Estimates, Shares Drop Over 9% as Revenue and EPS Fall Short ↗
May 06, 2026
Via Chartmill
Alvotech (NASDAQ:ALVO) Reports Q4 Revenue Beat but Significant EPS Miss, Stock Falls on Weak Guidance ↗
March 18, 2026
Via Chartmill
News headline image
Alvotech (ALVO) Q4 2025 Earnings Transcript ↗
June 02, 2026
Via The Motley Fool
Topics Bonds
News headline image
Alvotech Plans June FDA Resubmissions, Sees Biosimilar Approvals by Year-End ↗
May 13, 2026
Via MarketBeat
News headline image
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility
May 11, 2026
From Alvotech
Via GlobeNewswire
News headline image
Alvotech (ALVO) Q1 2026 Earnings Transcript ↗
May 08, 2026
Via The Motley Fool
News headline image
Alvotech Q1 2026 Financial Results
May 06, 2026
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces a Change in its Executive Team
April 30, 2026
From Alvotech
Via GlobeNewswire
News headline image
Alvotech to Report Financial Results for the First Quarter of 2026
April 24, 2026
From Alvotech
Via GlobeNewswire
Wondering what's happening in today's after-hours session? ↗
April 07, 2026
Via Chartmill
News headline image
Alvotech Files Annual Report with the SEC
March 30, 2026
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Q4 2025 and Full Year 2025 Financial Results
March 18, 2026
From Alvotech
Via GlobeNewswire
News headline image
Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results
March 04, 2026
From Alvotech
Via GlobeNewswire
News headline image
ALVO INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alvotech
February 23, 2026
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
Why Is ALVO Stock Rising Pre-Market Today? ↗
February 05, 2026
Via Stocktwits
News headline image
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
February 05, 2026
From Alvotech
Via GlobeNewswire
News headline image
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
February 02, 2026
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg
January 29, 2026
From Alvotech
Via GlobeNewswire
News headline image
The High-Stakes Balancing Act: Johnson & Johnson Braces for Q4 Earnings Amid Patent Cliffs and MedTech Expansion
January 20, 2026
Via MarketMinute
Topics Bankruptcy Earnings Economy
News headline image
Bragar Eagel & Squire, P.C. Continues Investigations into Alvotech and Beyond Meat on Behalf of Stockholders and Encourages Investors to Contact the Firm
January 13, 2026
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
January 09, 2026
From The Rosen Law Firm PA
Via GlobeNewswire

Frequently Asked Questions

Is Alvotech - Ordinary Shares publicly traded?
Yes, Alvotech - Ordinary Shares is publicly traded.
What exchange does Alvotech - Ordinary Shares trade on?
Alvotech - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Alvotech - Ordinary Shares?
The ticker symbol for Alvotech - Ordinary Shares is ALVO on the Nasdaq Stock Market
What is the current price of Alvotech - Ordinary Shares?
The current price of Alvotech - Ordinary Shares is 3.740
When was Alvotech - Ordinary Shares last traded?
The last trade of Alvotech - Ordinary Shares was at 06/04/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap